RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Francisella tularensis

This is a "connection" page, showing publications Bernard Arulanandam has written about Francisella tularensis.
Connection Strength

6.854
  1. Rodriguez AR, Yu JJ, Navara C, Chambers JP, Guentzel MN, Arulanandam BP. Contribution of Fc?RI-associated vesicles to mast cell-macrophage communication following Francisella tularensis infection. Innate Immun. 2016 10; 22(7):567-74.
    View in: PubMed
    Score: 0.535
  2. Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
    View in: PubMed
    Score: 0.522
  3. Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
    View in: PubMed
    Score: 0.411
  4. Hunter C, Rodriguez A, Yu JJ, Chambers J, Guentzel MN, Arulanandam B. Comparison of bone marrow-derived and mucosal mast cells in controlling intramacrophage Francisella tularensis replication. Exp Biol Med (Maywood). 2012 Jun; 237(6):617-21.
    View in: PubMed
    Score: 0.400
  5. Rodriguez AR, Yu JJ, Guentzel MN, Navara CS, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis. J Immunol. 2012 Jun 01; 188(11):5604-11.
    View in: PubMed
    Score: 0.396
  6. Sanapala S, Yu JJ, Murthy AK, Li W, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ?fopC vaccine strain. Infect Immun. 2012 Jun; 80(6):2177-85.
    View in: PubMed
    Score: 0.395
  7. Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Front Cell Infect Microbiol. 2011; 1:20.
    View in: PubMed
    Score: 0.387
  8. Thathiah P, Sanapala S, Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Forsthuber TG, Chambers JP, Arulanandam BP. Non-FceR bearing mast cells secrete sufficient interleukin-4 to control Francisella tularensis replication within macrophages. Cytokine. 2011 Aug; 55(2):211-20.
    View in: PubMed
    Score: 0.371
  9. Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification. Mucosal Immunol. 2011 Mar; 4(2):217-26.
    View in: PubMed
    Score: 0.355
  10. Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010 Apr 01; 5(4):e9952.
    View in: PubMed
    Score: 0.343
  11. Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 2010 Feb; 17(2):215-22.
    View in: PubMed
    Score: 0.336
  12. Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
    View in: PubMed
    Score: 0.328
  13. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
    View in: PubMed
    Score: 0.317
  14. Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
    View in: PubMed
    Score: 0.304
  15. Yu JJ, Raulie EK, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge. Eur J Clin Microbiol Infect Dis. 2008 Apr; 27(4):323-5.
    View in: PubMed
    Score: 0.293
  16. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
    View in: PubMed
    Score: 0.237
  17. Nguyen JQ, Zogaj X, Adelani AA, Chu P, Yu JJ, Arulanandam BP, Klose KE. Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis. J Vis Exp. 2017 09 30; (127).
    View in: PubMed
    Score: 0.144
  18. Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog. 2014 Oct; 10(10):e1004439.
    View in: PubMed
    Score: 0.118
  19. Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112?iglB::fljB. Vaccine. 2014 Sep 08; 32(40):5234-40.
    View in: PubMed
    Score: 0.116
  20. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, Garg N, Dhiman M, Pyles RB, Arulanandam B, Miller AL, Popov VL, Soong L, Carlsen ED, Coletta C, Szabo C, Almeida IC. Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med. 2013 Aug 28; 19:263-75.
    View in: PubMed
    Score: 0.109
  21. Chu P, Rodriguez AR, Arulanandam BP, Klose KE. Tryptophan prototrophy contributes to Francisella tularensis evasion of gamma interferon-mediated host defense. Infect Immun. 2011 Jun; 79(6):2356-61.
    View in: PubMed
    Score: 0.092
  22. Barker JR, Chong A, Wehrly TD, Yu JJ, Rodriguez SA, Liu J, Celli J, Arulanandam BP, Klose KE. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence. Mol Microbiol. 2009 Dec; 74(6):1459-70.
    View in: PubMed
    Score: 0.084
  23. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
    View in: PubMed
    Score: 0.075
  24. Rodriguez SA, Yu JJ, Davis G, Arulanandam BP, Klose KE. Targeted inactivation of francisella tularensis genes by group II introns. Appl Environ Microbiol. 2008 May; 74(9):2619-26.
    View in: PubMed
    Score: 0.074
  25. Lauriano CM, Barker JR, Yoon SS, Nano FE, Arulanandam BP, Hassett DJ, Klose KE. MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc Natl Acad Sci U S A. 2004 Mar 23; 101(12):4246-9.
    View in: PubMed
    Score: 0.056
  26. Lauriano CM, Barker JR, Nano FE, Arulanandam BP, Klose KE. Allelic exchange in Francisella tularensis using PCR products. FEMS Microbiol Lett. 2003 Dec 12; 229(2):195-202.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support